Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
0.6277
-0.0392 (-5.88%)
At close: Nov 20, 2026, 4:00 PM EST
0.6347
+0.0070 (1.12%)
After-hours: Nov 20, 2026, 7:37 PM EST
Allogene Therapeutics Employees
As of December 31, 2025, Allogene Therapeutics had 152 total employees, including 150 full-time and 2 part-time employees. The number of employees decreased by 77 or 33.62% compared to the previous year. That makes Allogene Therapeutics the 28,715th largest employer in the world and 3,617th in the United States.
Employees
152
Change (1Y)
-77
Growth (1Y)
-33.62%
Revenue / Employee
$30,526
Profits / Employee
-$1,147,783
Market Cap
217.48M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 152 | -77 | -33.62% | 150 | 2 |
| Dec 31, 2024 | 229 | -4 | -1.72% | 226 | 3 |
| Dec 31, 2023 | 233 | -128 | -35.46% | 232 | 1 |
| Dec 31, 2022 | 361 | 51 | 16.45% | 359 | 2 |
| Sep 30, 2022 | 356 | 55 | 18.27% | 356 | 0 |
| Jun 30, 2022 | 344 | 59 | 20.70% | 344 | 0 |
| Mar 31, 2022 | 334 | 58 | 21.01% | 334 | 0 |
| Dec 31, 2021 | 310 | 45 | 16.98% | 308 | 2 |
| Sep 30, 2021 | 301 | 37 | 14.02% | 301 | 0 |
| Jun 30, 2021 | 285 | 49 | 20.76% | 285 | 0 |
| Mar 31, 2021 | 276 | 61 | 28.37% | 276 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Cabaletta Bio | 158 |
| Arcturus Therapeutics Holdings | 111 |
| Keros Therapeutics | 87 |
| Century Therapeutics | 78 |
| Enanta Pharmaceuticals | 74 |
| Lexeo Therapeutics | 68 |
ALLO News
- 2 days ago - Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access - GlobeNewsWire
- 4 days ago - Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 6 days ago - Allogene Therapeutics Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 12 days ago - Allogene Therapeutics reports clinical data from RESOLUTION study - TheFly
- 12 days ago - Allogene Therapeutics Transcript: Study update - Transcripts
- 12 days ago - Allogene Therapeutics Press release: Study update - Filings
- 12 days ago - Allogene Therapeutics Slides: Study update - Filings
- 13 days ago - Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease - GlobeNewsWire